PubMed HealthSearch

PubMed · 9534732

Bone densitometry: current status and future prospects.

Abstract

Over the past decade, growing awareness of the impact of osteoporosis on the elderly population and the consequent costs of healthcare have stimulated development of new treatments to prevent fractures, together with new imaging technologies to assist in diagnosis. With its ability to perform high-precision measurements of bone mineral density (BMD) in the spine and hip, dual X-ray absorptiometry (DXA) is well suited to meet this latter need. However, there is continuing interest in smaller, less expensive, systems for assessing the peripheral skeleton. These include peripheral DXA scanning of the distal forearm and a variety of devices for performing quantitative ultrasound (QUS) measurements of broad-band ultrasonic attenuation (BUA) and speed of sound (SOS) in bone. Pivotal to all these developments is the demonstration in prospective studies that new technologies can reliably identify patients at risk of osteoporotic fractures. Whether DXA technology can meet the anticipated need for wider provision of diagnostic services is uncertain at present. The likely alternative is bone ultrasound. Although QUS technology is substantially cheaper than DXA and has proved its ability to predict fracture risk in the elderly, it is less precise, there is a lack of appropriate phantoms for quality control and there are doubts about how to interpret results in younger women.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G M Blake, C C Glüer, I Fogelman. 1997. Bone densitometry: current status and future prospects.. https://doi.org/10.1259/bjr.1997.0022

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Bone mineral density and laboratory evaluation of a type II autosomal dominant osteopetrosis carrier.

Type II autosomal dominant osteopetrosis (ADO2) is an inherited disorder characterized by increased skeletal mass and characteristic abnormalities evident on radiography. Although previous investigators have described nonpenetrant individuals (carriers), it is not known whether carriers manifest subtle abnormalities. We hypothesized that ADO2 carriers would have an abnormality of osteoclast function that would lead to changes in bone mineral density (BMD), in serum tartrate-resistant acid phosphatase (TRAP), or in creatine kinase isoenzyme BB (CK-BB) levels that would permit carrier recognition. We identified a female carrier in a well-established ADO2 family and measured BMD, serum TRAP, and CK-BB concentrations. She had normal BMD, serum TRAP, and CK-BB concentrations. Thus, these measurements cannot be used to exclude carrier status in individuals who are seen for genetic counseling. However, measurements in other asymptotic carriers are necessary before concluding that these measurements are normal in all or most nonpenetrant individuals.

Absorptiometry, Photon

Treatment of osteoporosis with MMP inhibitors.

In the current study, we examined the effects of minocycline on the osteopenia of ovariectomized (OVX) aged rats using the marrow ablation model. This injury induces rapid bone formation followed by bone resorption in the marrow cavity. Old female rats were randomly divided into five groups: sham, OVX, OVX + minocycline (5-15 mg/day, orally), OVX + 17 beta-estradiol (25 micrograms/day, subcutaneously), and OVX + both agents. Rats were OVX, treated with minocycline and/or estrogen, followed by marrow ablation. Bone samples were collected 16 days post-marrow ablation. X-ray radiography of bones operated on showed that treatment of OVX old rats with minocycline increased bone mass in diaphyseal region. Diaphyseal bone mineral density (BMD) was measured by DEXA scan. Diaphyseal BMD of OVX rats was increased 17-25% by treatment with 5-15 mg of minocycline or 17 beta-estradiol. The effects of minocycline and estrogen treatments on the expression of osteoblast and osteoclast markers were also examined. Northern and dot blot analysis of RNA samples showed that treatment of OVX aged rats with minocycline increased the expression of type I collagen (COL I) (49%) and decreased that of interleukin-6 (IL-6) (31%). In contrast, estrogen treatment decreased the expression of interleukin-6 (IL-6) (39%), carbonic anhydrase II (CA II) (36%), and osteopontin (OP) (37%). Neither minocycline nor 17 beta-estradiol had an effect on the expression of osteocalcin (OC) and alkaline phosphatase (AP). To elucidate the mechanism by which minocycline prevented the loss of bone in OVX aged rats, we examined the colony-formation potential of bone marrow stromal cells in ex vivo cultures. Minocycline stimulated the colony-forming efficiency of marrow stromal cells derived from old animals. We have therefore concluded that the modest increase in BMD noted in OVX aged rats, in response to minocycline treatment, may be due to a change in bone remodeling that favors bone formation; and the anabolic effect of minocycline is likely due to its effect on the expression of COL I and/or the metabolism of osteoprogenitor cells.

Absorptiometry, Photon